Stock News Staff

SAExploration Holdings, Inc. (NASDAQ:SAEX) at Top of Sector Performance

SAExploration Holdings, Inc. (NASDAQ:SAEX)

SAExploration Holdings, Inc. (NASDAQ:SAEX) stock is up over 12.5% in early trading on a volume six times higher than the pro-rated daily average. This morning, SAEX shares are the best performers in the “Oil & Gas Equipment & Services” sector.

SAExploration Holdings, Inc. (NASDAQ:SAEX)

SAExploration Holdings, Inc. (NASDAQ:SAEX), headquartered in Houston TX, is an oilfield services company offering vertically-integrated seismic data acquisition and logistical support services in remote and complex environments. SAE operates crews around the world, performing major projects for major integrated oil companies, national oil companies, and large independent oil and gas exploration companies. Operations are supported through a presence in Houston, Alaska, Canada, Peru, Colombia, Bolivia, Brazil, and New Zealand.

Circumstances, possibly hurricane related, forced the company to reschedule its Q2 2017 earnings report for almost three weeks. However, last week the company announced plans to release its unaudited consolidated Q3 2017 financial results on Wednesday, November 8, 2017 after close of trading.

SAEX Stock Performance

With a market capitalization of $18 million, SAExploration Holdings, Inc. (NASDAQ:SAEX) is considered a nano-cap company. However, as a company in the energy sector, it has a large operating cashflow in the neighborhood of $160 million annually.

Earnings have been historically poor for the company. After posting a per share profit of $234.59 in 2012, they followed that stellar performance up with an EPS loss of (-$283.89) in 2013, and (-$383.52) in 2014. Those massive losses were followed by smaller EPS losses of (-$84.55) in 2015, and (-$6.13) in 2016. In 2016, the company also increased the number of outstanding shares, and diluted shareholder equity, from 120,000 to 4.08 million.

Institutions have decreased their shareholdings in SAEX stock by over 30%. Year-to-date, the stock is down almost 75%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SAEX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Seanergy Maritime Holdings Corp. (NASDAQ:SHIP)

High Hopes for Seanergy Maritime Holdings Corp. (NASDAQ:SHIP) Earnings

Seanergy Maritime Holdings Corp. (NASDAQ:SHIP)

Seanergy Maritime Holdings Corp. (NASDAQ:SHIP) shares are 8.5% higher in early trading on a volume over 20 times larger than the daily average. Speculation is that traders are bidding up the price of the stock in front of their Q3 earnings report, due before the market opens tomorrow, in hopes that it will be a repeat of their Q2 report that saw massive increases in net revenues compared to the same period in 2016. Net revenues for Q2 2017 were reported up 125% compared to Q2 2016 and up 38% from Q1 2017.

Seanergy Maritime Holdings Corp. (NASDAQ:SHIP)

Dry-Bulk Shipping Rates

Also at play are higher bulk shipping rates that could lend support to such speculation. According to Seatrade Maritime News, “The Baltic Dry Index (BDI) achieved a three-year high at 1,588 last Tuesday [October 24, 2017], thanks to the rally seen among the industrial commodities.” However, interested parties should not that the article finishes with the following observation “With downtrend seen across the dry bulk rates, one wonders if the BDI can continue to push for further height again. However, the freight rates are still in the strong position currently with the support of the commodities prices rally. Perhaps, the market may see another upswing with the return of the traders from the Coaltrans conference.”

Seanergy Maritime Holdings Corp. (NASDAQ:SHIP) is an Glyfada, Greece based shipping company that owns and operates dry bulk shipping assets. Seanergy currently owns eleven dry bulk carriers, consisting of nine Capesizes and two Supramaxes, with a combined cargo-carrying capacity of approximately 1,682,582 dwt and an average fleet age of about 8.4 years. The company operates internationally and is incorporated in the Marshall Islands with executive offices in Athens, Greece and an office in Hong Kong.

SHIP Stock Performance

From 2012 until the end of 2014, the number of outstanding SHIP shares was stable. Then in 2015 the number increased to 10.77 million, then increased in 2016 to 20.55 million. Such actions heavily dilute shareholder equity and are a likely factor with the resistance of long-term investors to embrace the stock.

Investors have also not been keen on the erratic annual sales figures. In 2012, Seanergy Maritime Holdings Corp. (NASDAQ:SHIP) posted a sales figure of $55.6 billion. In the years that followed the annual sale figures were, in billions of $USD, $23.1, $2.0, $11.2, and $34.7.

Analysts have a consensus, one-year price target on SHIP of $2.00.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SHIP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Dextera Surgical Inc (NASDAQ:DXTR)

Will Dextera Surgical Inc (NASDAQ:DXTR) Ever Fly High Again?

Dextera Surgical Inc (NASDAQ:DXTR)

In 2011, shares of Dextera Surgical Inc (NASDAQ:DXTR) were trading above $50. Today the stock is trading below $0.20 as investors await the company’s Q1 2018 earnings announcement. The announcement will take place on Thursday, November 9, 2017, after the markets close. Analysts are expecting a loss of (-$0.06) per share.

NASDAQ:DXTR

DXTR stock last traded above the $1 level in May of 2017. This is not only a psychologically important level, but it also has a regulatory aspect to it. Section 5550(a)(2) of the Nasdaq’s Equity Rules guide states: “(a) Continued Listing Requirements for Primary Equity Securities: (2) Minimum bid price of at least $1 per share.” Frequently companies that in violation of the “$1 Bid” NASDAQ rule complete a reverse stock split to maintain compliance. So far, there has been no news on such an eventuality from Dextera.

Dextera Surgical Inc (NASDAQ:DXTR) designs and manufactures proprietary stapling devices for minimally invasive surgical procedures. In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted, or robotic-assisted surgical procedures annually. Dextera Surgical also markets the only automated anastomosis devices for coronary artery bypass graft (CABG) surgery on the market today: the C-Port® Distal Anastomosis Systems and PAS-Port® Proximal Anastomosis System.

DXTR Stock

Despite the multi-year downtrend and the recent EPS losses, two analysts rate DXTR stock as a “Strong Buy” while one rates DXTR stock as a “Hold”. Their consensus, one-year price target is $0.70. Earnings were projected to be -29% for 2017 but are projected at +16% for next year.

DXTR shareholders have had a rough 2017 so far. Year-to-date, DXTR shares are down over 80% and for the year shares are down over 88%.

EPS for DXTR stock has been negative since 2012 but improved each year until 2016, then a loss of (-$2.33) was posted for 2017. Sales have been rather consistent. In 2013 sales were posted at $3.5 million and that number did not substantially change over the next four years.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DXTR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Will Earnings Announcement Push Endocyte, Inc. (NASDAQ:ECYT) Over the Top?

Endocyte, Inc. (NASDAQ:ECYT)

Endocyte, Inc. (NASDAQ:ECYT), headquartered in West Lafayette, Indiana, will be announcing their Q3 20187 earnings after the close of the market on Monday, November 6, 2017. ACYT shares traded at less than half their monthly average volume on Friday as traders sat on the sidelines in anticipation of the news.

Endocyte, Inc. (NASDAQ:ECYT)

Endocyte, Inc. (NASDAQ:ECYT), is a biopharmaceutical company that develops therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create therapies for personalized targeted therapies.  The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells.  This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone.

ECYT Stock Review

At the beginning of October, ECYT stock jumped over 150% after the company announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH. ABX GmbH is a German developer and manufacturer of chemicals for the nuclear medicine industry. The day after the announcement, ECYT stock hit a new 52-week high of $6.55 – well above their 52-week low of $1.17, which had been established less than 60 days earlier.

Since establishing that 52-week high, ECYT shares have retreated. The low for October was $4.14 and, three times since then, shares traded over $5, but then retreated below that psychologically important level as sellers stepped in.

Year-to-date ECYT shares are up over 96% but are down over the past month by 12%. Three firms follow Endocyte, Inc. (NASDAQ:ECYT). Two rate ECYT shares as a “Strong Buy”, while one rates the shares a “Hold”.

The last four quarterly earnings announcements from Endocyte, Inc. (NASDAQ:ECYT) have either met or beat analyst expectations. For Q3, 2017 analysts are forecasting a per share loss between (-$0.25) and (-$0.30).

Financial ratios for Endocyte, Inc. (NASDAQ:ECYT) appear very healthy. The biotech firm has a cash per share figure of $2.96. Published reports put their current ratio at a robust 22.8. A company’s current ratio is a comparison of current assets to current liabilities. It is calculated by dividing the company’s current assets by its current liabilities. Potential creditors use the current ratio to measure a company’s liquidity or ability to pay off short-term debts.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ECYT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Gevo, Inc. (NASDAQ:GEVO)

Will Gevo, Inc. (NASDAQ:GEVO) Earnings Surprise?

Gevo, Inc. (NASDAQ:GEVO)

Gevo, Inc. (NASDAQ:GEVO) will be releasing their Q3 2017 earnings announcement after the market closes on Monday, November 6, 2017. According to reports, industry analysts are expecting Gevo to report a (-$0.41) per share loss for Q3 2017.

Gevo, Inc. (NASDAQ:GEVO)

Gevo, Inc. (NASDAQ:GEVO), based in Englewood, Colorado, is a green technology and biofuels company. Gevo has developed proprietary technology to produce isobutanol, as well as related products, from renewable feedstocks. Gevo’s business focuses on bio-based alternatives to petroleum-based products. Gevo produces isobutanol, ethanol, and high-value animal feed at its fermentation plant in Luverne, Minnesota.

Gevo Q3 Business Advances

On July 25, 2017, Gevo announced, working with Praj Industries Ltd., that Gevo’s proprietary isobutanol technology would be available for licensing to sugar-cane processors. Licensing efforts have focused on Praj plants located in India, South America and South-East Asia, with initial capacity targeted to come on-line in 2019 or 2020.

On October 9, 2017, Gevo, Inc. (NASDAQ:GEVO) announced that it will be partnering with the Los Alamos National Laboratory (LANL) on a project to improve the energy density of certain Gevo high energy density fuels (HEDFs), such as its alcohol-to-jet-fuel (ATJ). HEDFs are currently used in U.S. military air and sea-launched cruise missiles. If this project is successful in scaling HEDFs cost-effectively, there may be an even broader application in the general aviation sector.

GEVO Stock Performance

GEVO stock has been trading under $1 since mid-May. Technically, this puts the company in violation of NASDAQ Rule 5550(a)(2) which states that “(a) Continued Listing Requirements for Primary Equity Securities: (2) Minimum bid price of at least $1 per share.”

When the performance of Gevo, Inc. (NASDAQ:GEVO) shares is adjusted for dilution, the per share losses seem eye-popping. In 2012 the per share loss was (-$558.37). That loss was spread out over just 110,000 outstanding shares in 2012. By 2016 the per share loss was (-$9.68) and the number of outstanding shares was 3.85 million.

Two firms follow Gevo, Inc. (NASDAQ:GEVO). One rates GEVO stock as a “Strong Buy” while the other rates the shares as a “Hold”. Their analysts’ consensus, one-year price target is $8.50. However, GEVO stock has lost over 80% of its value in the past year and is 92% below its 52-week high of $9.00.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $GEVO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Market Awaits Medical Transcription Billing Corp (NASDAQ:MTBC) Earnings

Medical Transcription Billing Corp (NASDAQ:MTBC)

Medical Transcription Billing Corp (NASDAQ:MTBC) is scheduled to release their Q3 earnings report today before the market opens. In August, the company placed its full year 2017 guidance at $31 to $32 million. That level of revenue represents a 27% to 31% growth over 2016 revenue. The company expects 2017 adjusted EBITDA to be $2.0 to $2.5 million.

Medical Transcription Billing Corp (NASDAQ:MTBC)

Medical Transcription Billing Corp (NASDAQ:MTBC) is a healthcare information technology company that provides a fully integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. Their platform is designed to help customers increase revenues, streamline workflows, and make better business and clinical decisions.

MTBC Stock

MTBC shares have gained over 450% year-to-date and almost 50% in just the last month. That has pushed MTBC stock from its 52-week low of $0.29, to its 52-week high, achieved in October, of $5.44.

During that time, the company repaid its debt. To pay off that debt, Medical Transcription Billing Corp (NASDAQ:MTBC) issued $7.9 million worth of Series A Preferred Stock. The move worked, according to observers, as revenues have exceeded cash operating expenses since May 2017.

Over the years, MTBC has not been able to transform annual increases in sales to profits. In 2012, the per share profit was just $0.01. Annual per share losses followed of (-$0.02), (-$0.64), (-$0.46), and, for 2016, (-$0.95).

However, sales did increase year on year. In 2012, sales were reported at $10 million. That annual figure was followed by annual figures of $10.5 million, $18.3 million, 23.1 million, and in 2016, $24.5 million.

It should be noted that the company has quite a number of short-sellers betting against it. As of November 3, 2017, over 15% of the stock’s float was being held in a short position.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MTBC and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

BioScrip Inc (NASDAQ:BIOS) Weathering Adversity

BioScrip Inc (NASDAQ:BIOS)

On Friday, BioScrip Inc (NASDAQ:BIOS) stock rebounded 8% – the day after the biotech’s shares dropped over 20% following a disappointing earnings announcement. On Thursday BIOS shares gapped down then sold off further in response to an earnings announcement of a loss of (-$12.5) million, or (-$0.125) per share, million for Q3 2017. Reports suggest that analysts were expecting a small loss of (-$0.10) per share. Revenues came in at $198.7 million which was also below the $203 million that analysts were expecting.

BioScrip Inc (NASDAQ:BIOS)

BioScrip Business

Denver, CO-based BioScrip Inc (NASDAQ:BIOS) prepares, delivers, administers, and monitors pharmaceutical treatments that are administered to patients in their own homes. BioScrip, Inc. also offers its services at outpatient clinics, nursing facilities, physician’s offices, and ambulatory infusion centers. The company markets and sells its products and services through sales and marketing representatives, payor relationships, and other government programs.

Along with the earnings announcement, BioScrip Inc (NASDAQ:BIOS) provided an update to its 2017 guidance. The company stated that revenues for the full year will be between $805.0 million to $810.0 million. These figures were lowered from earlier in the year due to the disruption from the hurricanes and the UnitedHealthcare contract transition. The Company has also updated its adjusted EBITDA guidance to a range of $42.0 million to $44.0 million 2017.

Daniel E. Greenleaf, President and Chief Executive Officer, made a statement in conjunction with the earnings release “BioScrip delivered adjusted EBITDA of $13.0 million during the third quarter of 2017, while completing the UnitedHealthcare contract transition and enduring disruption from both Hurricane Harvey and Hurricane Irma, which impacted 12 of our branches…. The turnaround plan is on schedule, driven by success in our CORE initiatives which has driven much improved and sustainable profitability and cash flow. With the UnitedHealthcare contract transition complete, we look forward to Core revenue acceleration.”

BIOS Stock Performance

In August, SunTrust upgrade its rating of BIOS shares to a “Buy” which aligned with the rating assigned by LakeStreet. The third firm that covers BioScrip Inc (NASDAQ:BIOS) is Barrington Research and they rate BIOS shares as an “Outperform”.

BioScrip’s annual sales figures increased each year from 2012, when the company reported $593.4 million, to 2015, when it reported $982.2 million. Then in 2016, sales dropped off and the company posted a sales figure of $935.6 million.

Earnings have been tough to come by for the company. Per share losses increased from 2012 (-$0.22) to 2015 (-$4.56) then contracted in 2016 (-$0.46).

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BIOS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

KEYW Holding Corp. (NASDAQ:KEYW)

KEYW Holding Corp. (NASDAQ:KEYW) Stock Craters!

KEYW Holding Corp. (NASDAQ:KEYW)

KEYW Holding Corp. (NASDAQ:KEYW) stock dropped over 33% on Friday after the company reported a Q3 loss of (-$4.2) million, or (-$0.08) per share, after reporting a profit for the same period a year earlier. Volume was over six times the listed daily average of 412,000. The earnings of the Hanover, Maryland-based company fell short of Wall Street expectations which had been for a $0.05 per share profit.

KEYW Holding Corp. (NASDAQ:KEYW)

KEYW Holding Corp. (NASDAQ:KEYW) is a national security solutions provider for the Intelligence, Cyber, and Counterterrorism agencies. KEYW supports the collection, processing, analysis and dissemination of information across the full spectrum of America’s national security missions. The company employs over 2,000 professionals in the industry who address such complex problems as preventing cyber threats, transforming data into intelligence, and combating global terrorism.

KEYW Stock Performance

KEYW shares had traded over $12 at the beginning of 2017 but experienced a consistent slide to the current $5 level. Year-to-date, KEYW Holding Corp. (NASDAQ:KEYW) stock has lost over 56% and lost over 30% in the last week alone. The latest downturn eradicated the old 52-week low of $6.18.

Some observers look at the performance of the stock and maintain a “wait and see” posture. However, analysts have been reiterating or upgrading their ratings on KEYW stock throughout the year. In 2017, RBC Capital Markets initiated coverage with an “Outperform” rating and a $12 price target. In May, Maxim Group upgraded their rating from a “Hold” to a “Buy” with a $13 price target. That was followed, in August, by Drexel Hamilton raising their “Hold” rating to a “Buy”, then on Friday Maxim reiterated their rating but lowered their price target to $10 from $13.

KEYW Holding Corp. (NASDAQ:KEYW) has reported steady sales near the $300 million mark for the past four years. While sales growth has been absent, a concern for steady earnings seem to be the area of larger concern for investors. In 2012, 2014, and 2016, the company reported per share profits of $0.04, $0.18, and $0.05. However, 2013 and 2015 produced per share losses of (-$0.31) and (-$0.77).

Interested investors should not the high short-sale position that the market has established in the company – over 20% of the stock’s float is held short.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $KEYW and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

DURECT Corporation (NASDAQ:DRRX)

DURECT Corporation (NASDAQ:DRRX) Coming Back to Life?

DURECT Corporation (NASDAQ:DRRX)

On Friday, DRRX stock closed at $0.95, their highest valuation since the shares cratered following a disappointing Phase 3 report almost two weeks ago. Volume for the biotechnology company was heavy – almost three times the listed daily volume average.

DURECT Corporation (NASDAQ:DRRX) shares cratered over 60% on October 20, 2017 on a volume figure of over 8.6 million – DRRX stock previously had an average daily volume of just 456,000. Investors bailed on the biotechnology company after the biotechnology company announced that its drug candidate, Posimir failed to meet its primary efficacy endpoint of pain reduction in a statistical meaningful manner in the Phase 3 PERSIST study.

DRRX Q3 Financials

The biotechnology company reported $6.1 million in Q3 net income versus a net loss of $8.8 million in Q3 2016. DURECT Corporation (NASDAQ:DRRX) reported Q3 revenues of $20.7 compared to $3.7 million over the same period last year. Q3 R&D collaboration revenues were $5.6 million versus to $0.4 million in Q3 2016.

As part of their corporate update, the company informed the public that they signed a patent purchase agreement with Indivior for Durect’s RBP-7000, yielding DURECT a $12.5 million upfront payment, as well as a possible $5 million milestone payment and potential earn-out payments.

Durect – Sandoz License Agreement

DURECT Corporation (NASDAQ:DRRX) and Sandoz AG (“Sandoz”) entered into a license agreement to develop and market POSIMIR in the United States, and the agreement became effective in June 2017. DURECT retains commercialization rights in the rest of the world.  Under terms of the agreement, Sandoz made an upfront payment of $20 million, with the potential for up to an additional $43 million in milestone payments based on successful development and regulatory milestones, and up to an additional $230 million in sales-based milestones.

DURECT is responsible for the completion of the ongoing PERSIST Phase 3 clinical trial for POSIMIR as well as FDA interactions through approval.  DURECT Corporation (NASDAQ:DRRX)  also has certain manufacturing obligations under this agreement.

DURECT Corporation (NASDAQ:DRRX) posted a profit of ($0.16) per share in 2012. Since then, losses have been posted every year and in 2016 they posted their largest loss of (-$0.18) per share. In 2016 the company also their lowest sales figure of $14 million.

In July, 2017 Stifel issues an upgrade to DRRX shares – from a “Hold” to a “Buy”. Then, on October 20, 2017, Stifel and H.C. Wainwright downgraded DRRX stock to a “Hold” from a “Buy”. At that time, Stifel also issued a one-year price target of $0.90.

 

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

NASDAQ:IDRA

Idera Pharmaceuticals Inc (NASDAQ:IDRA) Moves Higher

Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock has apparently come under selling pressure at the end of the last five trading sessions. Even so, IDRA stock saw a 11.5% increase over the past week. Friday’s high of $1.83 was 38% higher than the 52-week low of $1.32 which was recently established on October 26, 2017.

IDRA stock had plummeted on October 26, after Idera Pharmaceuticals Inc (NASDAQ:IDRA) announced pricing a share offering at $1.50 – the previous close for IDRA shares was $2.03. The offering was for 33,333,334 shares of its common stock with a 30-day option to for the underwriters to purchase up to an additional 5,000,000 shares of common stock.

NASDAQ:IDRA

About Idera

Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s development program focuses on boosting the immune system to play a more powerful role in fighting cancer, and ultimately increase the number of people who can benefit from immunotherapy. Idera invests in research and development, and works with investigators and partners to address the unmet needs of patients who are suffering from rare, life-threatening diseases.

IDRA Stock Performance

JP Morgan, Wedbush Securities, Piper Jaffray, and Baird all follow Idera Pharmaceuticals Inc (NASDAQ:IDRA) and rate the shares as a “Strong Buy”. The listed consensus one-year price target is $5.75. Year-to-date ODRA shares are up only 16%. For the year, IDRA stock is up 19.2%.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) has posted per share losses since 2012 (-$0.81) but the trend has been favorable and the loss for 2016 was just (-$0.30). Last year the company posted their first significant sales figure of $16.2 million. The downside for investors has been the annual dilution as outstanding shares have increased every year since 2012 when the number of outstanding shares was 27.64 million. But by the end of 2016, and prior to the most recent share offering, over 127.6 million shares were listed as outstanding.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IDRA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.